Skip to main content
Top
Published in: Clinical Rheumatology 5/2011

01-05-2011 | Brief Report

Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis

Authors: Laura Muntean, Marena Rojas-Vargas, Pilar Font, Siao-Pin Simon, Simona Rednic, Ruxandra Schiotis, Simona Stefan, Maria M. Tamas, Horatiu D. Bolosiu, Eduardo Collantes-Estévez

Published in: Clinical Rheumatology | Issue 5/2011

Login to get access

Abstract

The purpose of this study is to evaluate bone mineral density (BMD) and bone turnover markers in men with ankylosing spondylitis (AS) and to determine their relationship with clinical features and disease activity. Serum carboxi terminal cross-linked telopeptide of type I collagen (CTX), osteocalcin (OC) levels, and BMD of lumbar spine and proximal femur were evaluated in 44 males with AS, 18–60 years of age, and compared with those of 39 age-matched healthy men. Men with AS had a significantly lower BMD at the femoral neck and total hip as compared to age-matched controls (all p < 0.01). Osteopaenia or osteoporosis was found in 59.5% AS patients at the lumbar spine and in 47.7% at the femoral neck. Mean serum levels of OC and CTX were similar in AS patients and controls. There were no significant differences in BMD and bone turnover markers when comparing subgroups stratified according to disease duration or presence of peripheral arthritis. No correlations were found between disease activity markers and BMD or OC and CTX. In a cohort of relatively young males with AS, we found a high incidence of osteopaenia and osteoporosis. Disease activity and duration did not show any significant influence on BMD or serum levels of OC and CTX.
Literature
1.
go back to reference Toussirot E, Wendling D (2000) Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 18(Suppl 21):S16–S20 Toussirot E, Wendling D (2000) Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 18(Suppl 21):S16–S20
2.
go back to reference Wendling D (2007) Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis? J Rheumatol 34:1647–1649PubMed Wendling D (2007) Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis? J Rheumatol 34:1647–1649PubMed
3.
go back to reference Marhoffer W, Schatz H, Stracke H et al (1991) Serum osteocalcin levels in rheumatoid arthritis: a marker for accelerated bone turnover in late onset rheumatoid arthritis. J Rheumatol 18:1158–1162PubMed Marhoffer W, Schatz H, Stracke H et al (1991) Serum osteocalcin levels in rheumatoid arthritis: a marker for accelerated bone turnover in late onset rheumatoid arthritis. J Rheumatol 18:1158–1162PubMed
4.
go back to reference Rosen HN, Moses AC, Garber J et al (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103PubMedCrossRef Rosen HN, Moses AC, Garber J et al (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103PubMedCrossRef
5.
go back to reference Van Der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef Van Der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef
6.
go back to reference Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Disease Activity Index. J Rheumatol 21:2286–2291PubMed
7.
go back to reference Calin A, Garret S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21:2281–2285PubMed Calin A, Garret S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21:2281–2285PubMed
8.
go back to reference World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. WHO, Geneva World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. WHO, Geneva
9.
go back to reference Donnelly S, Doyle DV, Denton A et al (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53:117–121PubMedCrossRef Donnelly S, Doyle DV, Denton A et al (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53:117–121PubMedCrossRef
10.
go back to reference Capaci K, Hepguler S, Argin M et al (2003) Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J 44:379–384PubMed Capaci K, Hepguler S, Argin M et al (2003) Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J 44:379–384PubMed
11.
go back to reference Baek HJ, Kang SW, Lee YJ et al (2005) Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 26:30–34PubMedCrossRef Baek HJ, Kang SW, Lee YJ et al (2005) Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 26:30–34PubMedCrossRef
12.
go back to reference Geusens P, Vosse D, van der Linden S (2007) Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 19:335–339PubMedCrossRef Geusens P, Vosse D, van der Linden S (2007) Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 19:335–339PubMedCrossRef
13.
go back to reference Bessant R, Keat A (2002) How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol 29:1511–1519PubMed Bessant R, Keat A (2002) How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol 29:1511–1519PubMed
14.
go back to reference Speden DJ, Calin AI, Ring FJ et al (2002) Bone mineral density, calcanean ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 29:516–521PubMed Speden DJ, Calin AI, Ring FJ et al (2002) Bone mineral density, calcanean ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 29:516–521PubMed
15.
go back to reference Toussirot E, Michel F, Wendling D (2001) Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. J Rheumatol 40:882–888CrossRef Toussirot E, Michel F, Wendling D (2001) Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. J Rheumatol 40:882–888CrossRef
16.
go back to reference Gratacós J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis. A follow-up study. Arthritis Rheum 42:2319–2324PubMedCrossRef Gratacós J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis. A follow-up study. Arthritis Rheum 42:2319–2324PubMedCrossRef
17.
go back to reference Maillefert JF, Aho LS, El Maghraoui A et al (2001) Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 12:605–609PubMedCrossRef Maillefert JF, Aho LS, El Maghraoui A et al (2001) Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 12:605–609PubMedCrossRef
18.
go back to reference Bronson WD, Walker SE, Hillman LS et al (1998) Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol 25:929–935PubMed Bronson WD, Walker SE, Hillman LS et al (1998) Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol 25:929–935PubMed
19.
go back to reference Toussirot E, Ricard-Blum S, Dumoulin G et al (1999) Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 38:21–27PubMedCrossRef Toussirot E, Ricard-Blum S, Dumoulin G et al (1999) Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 38:21–27PubMedCrossRef
20.
go back to reference Mitra D, Elvis DM, Collins AJ (1999) Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relantionship with bone mineral density and vertebral fractures. J Rheumatol 26:2201–2204PubMed Mitra D, Elvis DM, Collins AJ (1999) Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relantionship with bone mineral density and vertebral fractures. J Rheumatol 26:2201–2204PubMed
21.
go back to reference Borman P, Bodur H, Bingöl N et al (2001) Bone mineral density and bone turnover markers in a group of male ankylosing spondylitis patients: relationship to disease severity. J Clin Rheumatol 7:315–321PubMedCrossRef Borman P, Bodur H, Bingöl N et al (2001) Bone mineral density and bone turnover markers in a group of male ankylosing spondylitis patients: relationship to disease severity. J Clin Rheumatol 7:315–321PubMedCrossRef
22.
go back to reference El Maghraoui A, Borderie D, Cherruau B et al (1999) Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 26:2205–2209PubMed El Maghraoui A, Borderie D, Cherruau B et al (1999) Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 26:2205–2209PubMed
23.
go back to reference Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in ankylosing spondylitis. J Rheumatol 31:2236–2241PubMed Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in ankylosing spondylitis. J Rheumatol 31:2236–2241PubMed
Metadata
Title
Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis
Authors
Laura Muntean
Marena Rojas-Vargas
Pilar Font
Siao-Pin Simon
Simona Rednic
Ruxandra Schiotis
Simona Stefan
Maria M. Tamas
Horatiu D. Bolosiu
Eduardo Collantes-Estévez
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1648-3

Other articles of this Issue 5/2011

Clinical Rheumatology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.